Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections: Results of a Double-Blind, Randomized Comparative Phase III Trial

Página do item simplificado
dc.contributor.authorSolomkin J.S.
dc.contributor.authorYellin A.E.
dc.contributor.authorRotstein O.D.
dc.contributor.authorChristou N.V.
dc.contributor.authorDellinger E.P.
dc.contributor.authorTellado J.M.
dc.contributor.authorMalafaia O.
dc.contributor.authorFernandez A.
dc.contributor.authorChoe K.A.
dc.contributor.authorCarides A.
dc.contributor.authorSatishchandran V.
dc.contributor.authorTeppler H.
dc.date.accessioned2024-03-13T01:45:52Z
dc.date.available2024-03-13T01:45:52Z
dc.date.issued2003
dc.description.abstractObjective: To examine the clinical efficacy and safety of ertapenem, a novel β-lactam agent with wide activity against common pathogens encountered in intraabdominal infection. Summary Background Data: Ertapenem has a pharmacokinetic profile and antimicrobial spectrum that support the potential for use as a once-a-day agent for the treatment of common mixed aerobic and anaerobic infections. Methods: This prospective, randomized, controlled, and double-blind trial was conducted to compare the safety and efficacy of ertapenem with piperacillin/tazobactam as therapy following adequate surgical management of complicated intraabdominal infections. Results: Six hundred thirty-three patients were included in the modified intent-to-treat population, with 396 meeting all criteria for the evaluable population. Patients with a wide range of infections were enrolled; perforated or abscessed appendicitis was most common (approximately 60% in microbiologically evaluable population). A prospective, expert panel review was conducted to assess the adequacy of surgical source control in patients who were failures as a component of evaluability. For the modified intent-to-treat groups, 245 of 311 patients treated with ertapenem (79.3%) were cured, as were 232 of 304 (76.2) treated with piperacillin/tazobactam. One hundred seventy-six of 203 microbiologically evaluable patients treated with ertapenem (86.7%) were cured, as were 157 of the 193 (81.2%) treated with piperacillin/tazobactam. Conclusions: In this study, the efficacy of ertapenem 1 g once a day was equivalent to piperacillin/tazobactam 3.375 g every 6 hours in the treatment of a range of intraabdominal infections. Ertapenem was generally well tolerated and had a similar safety and tolerability profile to piperacillin/tazobactam. A formal process for review of adequacy of source control was found to be of benefit. The results of this trial suggest that ertapenem may be a useful option that could eliminate the need for combination and/or multidosed antibiotic regimens for the empiric treatment of intraabdominal infections.
dc.description.firstpage235
dc.description.issuenumber2
dc.description.lastpage245
dc.description.volume237
dc.identifier.doi10.1097/00000658-200302000-00013
dc.identifier.issn0003-4932
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/37977
dc.relation.ispartofAnnals of Surgery
dc.rightsAcesso Restrito
dc.titleErtapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections: Results of a Double-Blind, Randomized Comparative Phase III Trial
dc.typeArtigo
local.scopus.citations193
local.scopus.eid2-s2.0-0037315316
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0037315316&origin=inward
Arquivos
Coleções
Artigos de periódico